Concepedia

Publication | Closed Access

Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma

DOI

127

Citations

28

References

2000

Year

Lucie Heinzerling, Margarete Urbanek, Jens Oliver Funk, Stefan Peker, O. Bleck, K. Neuber, G�nter Burg, Peter Von Den Driesch, Reinhard Dummer
Cancer

Abstract

Intravenous therapy with the anti-CD20 antibody rituximab is a nontoxic and effective treatment for patients with primary cutaneous B-cell lymphoma.

References

YearCitations

Page 1